Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities

被引:205
作者
Banerjee, R
Bhatt, PM
Ravindra, NV
Desiraju, GR [1 ]
机构
[1] Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India
[2] GVK Biosci Private Ltd, Informat Div, Hyderabad 500016, Andhra Pradesh, India
关键词
D O I
10.1021/cg050125l
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Salts of active pharmaceutical ingredients (APIs) have been traditionally used in drug formulations because of improved properties with respect to solubility, stability, or bioavailability. Saccharin has been used as an acid for salt formation with APIs in a few cases hitherto. In this paper, we have explored the generality of this property and have isolated saccharinates of quinine, haloperidol, mirtazapine, pseudoephedrine, lamivudine, risperidone, sertraline, venlafaxine, zolpidem, and amlodipine. These salts have been characterized with single-crystal X-ray methods. The structures contain many hydrogen bonds of the O-H-... N(-), (N(+)-H...) N(-), N(+)-H-... O, N-H-... O, O-H-... O and N-H-... N type, with auxiliary C-H-... N(-) and C-H-... O interactions. These saccharinates are mostly very soluble in water when compared to the free base. Additionally, aqueous solutions of these API saccharinates are of moderate pH. Both these properties may be advantageous in the pharmaceutical industry. In general, most saccharinates would appear to have high water solubility, and this follows from the molecular structure of the anion, which is donor-poor and acceptor-rich in terms of hydrogen-bonding functionalities. If an API of insufficient basicity is treated with saccharin, it may form a hydrogen-bonded cocrystal wherein proton transfer from saccharin to the API does not take place. This phenomenon was found in the cocrystal saccharin-piroxicam.
引用
收藏
页码:2299 / 2309
页数:11
相关论文
共 81 条
[51]   SERTRALINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN DEPRESSION AND OBSESSIVE-COMPULSIVE DISORDER [J].
MURDOCH, D ;
MCTAVISH, D .
DRUGS, 1992, 44 (04) :604-624
[52]   Pseudopolymorphism: occurrences of hydrogen bonding organic solvents in molecular crystals [J].
Nangia, A ;
Desiraju, GR .
CHEMICAL COMMUNICATIONS, 1999, (07) :605-606
[53]  
Neau S. H., 2000, WATER INSOLUBLE DRUG, P405
[54]   Supramolecular synthesis by cocrystallization of oxalic and fumaric acid with diazanaphthalenes [J].
Olenik, B ;
Smolka, T ;
Boese, R ;
Sustmann, R .
CRYSTAL GROWTH & DESIGN, 2003, 3 (02) :183-188
[55]  
OOSTERBAAN MJM, Patent No. 20030190353
[56]   STRUCTURE OF 3-(2-[4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDINO]ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO-[1,2-A]PYRIMIDIN-4-ONE (RISPERIDONE) [J].
PEETERS, OM ;
BLATON, NM ;
DERANTER, CJ .
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1993, 49 :1698-1700
[57]   Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III [J].
Peterson, ML ;
Morissette, SL ;
McNulty, C ;
Goldsweig, A ;
Shaw, P ;
LeQuesne, M ;
Monagle, J ;
Encina, N ;
Marchionna, J ;
Johnson, A ;
Gonzalez-Zugasti, J ;
Lemmo, AV ;
Ellis, SJ ;
Cima, MJ ;
Almarsson, Ö .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (37) :10958-10959
[58]   Crystalline polymorph selection and discovery with polymer heteronuclei [J].
Price, CP ;
Grzesiak, AL ;
Matzger, AJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (15) :5512-5517
[59]  
PUTTIPEDDI M, 2002, HDB PHARM SALTS PROP, P19
[60]  
RADER K, 1982, Patent No. 4362730